低剂量氨鲁米特联合与不联合氢化可的松对绝经后乳腺癌患者内分泌影响的比较。
A comparison of the endocrine effects of low dose aminoglutethimide with and without hydrocortisone in postmenopausal breast cancer patients.
作者信息
Dowsett M, Harris A L, Stuart-Harris R, Hill M, Cantwell B M, Smith I E, Jeffcoate S L
出版信息
Br J Cancer. 1985 Oct;52(4):525-9. doi: 10.1038/bjc.1985.223.
Abstract
The endocrine effects of 125 mg (low dose) aminoglutethimide (AG) twice daily (b.d.) were compared with those of 125 mg AG + 20 mg hydrocortisone (HC) b.d. in 23 and 45 postmenopausal patients with advanced breast cancer, respectively. The patients in each group were drawn from two separate populations, but the mean age and weight of the groups were similar and there were no significant differences between the pretreatment serum levels of the hormones investigated. Serum oestrone and oestradiol levels were suppressed by both treatments, but there was a significantly greater suppression by AG + HC. This greater suppression is probably due to the observed increase in serum androstenedione (i.e. precursor) levels with AG alone, whilst with AG + HC these levels were found to be reduced. In terms of suppression of serum oestrogen levels it is of benefit to combine low dose AG with HC.
摘要
分别对23例和45例绝经后晚期乳腺癌患者进行研究，比较每日两次服用125毫克（低剂量）氨鲁米特（AG）与每日两次服用125毫克AG加20毫克氢化可的松（HC）的内分泌效应。每组患者来自两个不同群体，但两组的平均年龄和体重相似，所研究激素的治疗前血清水平之间无显著差异。两种治疗均能抑制血清雌酮和雌二醇水平，但AG + HC的抑制作用明显更强。这种更强的抑制作用可能是由于单独使用AG时血清雄烯二酮（即前体）水平升高，而使用AG + HC时这些水平降低。就抑制血清雌激素水平而言，低剂量AG与HC联合使用有益。
相似文献
1
A comparison of the endocrine effects of low dose aminoglutethimide with and without hydrocortisone in postmenopausal breast cancer patients.低剂量氨鲁米特联合与不联合氢化可的松对绝经后乳腺癌患者内分泌影响的比较。
Br J Cancer. 1985 Oct;52(4):525-9. doi: 10.1038/bjc.1985.223.
2
Hydrocortisone alone vs hydrocortisone plus aminoglutethimide: a comparison of the endocrine effects in postmenopausal breast cancer.单独使用氢化可的松与氢化可的松加氨鲁米特的比较：绝经后乳腺癌内分泌效应的对比
Eur J Cancer Clin Oncol. 1984 Apr;20(4):463-9. doi: 10.1016/0277-5379(84)90230-x.
3
Endocrine effects of low dose aminoglutethimide alone in advanced postmenopausal breast cancer.低剂量氨鲁米特单药对晚期绝经后乳腺癌的内分泌作用
Br J Cancer. 1983 May;47(5):621-7. doi: 10.1038/bjc.1983.100.
4
Endocrine effects of low dose aminoglutethimide with hydrocortisone--an optimal hormone suppressive regimen.低剂量氨鲁米特联合氢化可的松的内分泌效应——一种最佳激素抑制方案
Breast Cancer Res Treat. 1986;7 Suppl:S69-72.
5
Aminoglutethimide dose and hormone suppression in advanced breast cancer.氨鲁米特剂量与晚期乳腺癌的激素抑制
Eur J Cancer Clin Oncol. 1983 Apr;19(4):493-8. doi: 10.1016/0277-5379(83)90112-8.
6
Endocrine effects of low dose aminoglutethimide as an aromatase inhibitor in the treatment of breast cancer.低剂量氨鲁米特作为芳香化酶抑制剂治疗乳腺癌的内分泌效应
Clin Endocrinol (Oxf). 1985 Feb;22(2):219-26. doi: 10.1111/j.1365-2265.1985.tb01083.x.
7
Endocrine effects of aminoglutethimide plus hydrocortisone versus effects of high dose of hydrocortisone alone in postmenopausal metastatic breast cancer.氨鲁米特加氢化可的松与单独使用高剂量氢化可的松对绝经后转移性乳腺癌的内分泌影响
Eur J Cancer Clin Oncol. 1987 Sep;23(9):1349-56. doi: 10.1016/0277-5379(87)90119-2.
8
Endocrine and therapeutic effects of aminoglutethimide in premenopausal patients with breast cancer.氨鲁米特对绝经前乳腺癌患者的内分泌及治疗作用
J Clin Endocrinol Metab. 1982 Oct;55(4):718-22. doi: 10.1210/jcem-55-4-718.
9
Second line endocrine treatment of postmenopausal advanced breast cancer. Preliminary endocrine results of a 5-arm randomized phase II trial of medium vs low dose aminoglutethimide, with or without hydrocortisone vs hydrocortisone alone (EORTC 10861).绝经后晚期乳腺癌的二线内分泌治疗。一项五臂随机II期试验的初步内分泌结果：中剂量与低剂量氨鲁米特对比，加或不加氢化可的松与单用氢化可的松（欧洲癌症研究与治疗组织10861）
J Steroid Biochem Mol Biol. 1990 Dec 20;37(6):1013-9. doi: 10.1016/0960-0760(90)90459-x.
10
Endocrine changes associated with relapse in advanced breast cancer patients on aminoglutethimide therapy.接受氨鲁米特治疗的晚期乳腺癌患者复发相关的内分泌变化。
J Clin Endocrinol Metab. 1984 Jan;58(1):99-104. doi: 10.1210/jcem-58-1-99.
引用本文的文献
1
Comprehensive pharmacology and clinical efficacy of aromatase inhibitors.芳香化酶抑制剂的全面药理学与临床疗效
Drugs. 1999 Aug;58(2):233-55. doi: 10.2165/00003495-199958020-00003.
2
Plasma and urinary oestrogens in breast cancer patients on treatment with 4-hydroxyandrostenedione.接受4-羟基雄烯二酮治疗的乳腺癌患者的血浆和尿液雌激素
Br J Cancer. 1993 Aug;68(2):393-8. doi: 10.1038/bjc.1993.347.
3
First generation aromatase inhibitors--aminoglutethimide and testololactone.第一代芳香化酶抑制剂——氨鲁米特和睾内酯。
Breast Cancer Res Treat. 1994;30(1):57-80. doi: 10.1007/BF00682741.
4
Aromatase inhibition with 4-OHAndrostenedione after prior aromatase inhibition with aminoglutethimide in women with advanced breast cancer.在晚期乳腺癌女性中，先用氨鲁米特抑制芳香化酶后，再用4-羟基雄烯二酮抑制芳香化酶。
Breast Cancer Res Treat. 1995 Sep;35(3):249-53. doi: 10.1007/BF00665976.
5
Clinically relevant concentrations of verapamil do not enhance the sensitivity of human bone marrow CFU-GM to adriamycin and VP16.临床上相关浓度的维拉帕米不会增强人骨髓CFU - GM对阿霉素和依托泊苷的敏感性。
Br J Cancer. 1988 Jun;57(6):576-8. doi: 10.1038/bjc.1988.131.
6
Mechanisms of action of aminoglutethimide as endocrine therapy of breast cancer.氨鲁米特作为乳腺癌内分泌治疗的作用机制
Drugs. 1988 Jun;35(6):685-710. doi: 10.2165/00003495-198835060-00005.
7
Inherent adriamycin resistance in a murine tumour line: circumvention with verapamil and norverapamil.一种小鼠肿瘤细胞系的内在阿霉素耐药性：用维拉帕米和去甲维拉帕米克服
Br J Cancer. 1989 Jun;59(6):895-7. doi: 10.1038/bjc.1989.189.
8
Treatment of breast cancer with aromatase inhibitors--current status and future prospects.芳香化酶抑制剂治疗乳腺癌——现状与未来展望
Br J Cancer. 1989 Jul;60(1):5-8. doi: 10.1038/bjc.1989.208.
9
Alterations in the production rate and the metabolism of oestrone and oestrone sulphate in breast cancer patients treated with aminoglutethimide.用氨鲁米特治疗的乳腺癌患者中雌酮及硫酸雌酮生成率和代谢的改变。
Br J Cancer. 1989 Jul;60(1):107-11. doi: 10.1038/bjc.1989.231.
10
Aminoglutethimide enzyme induction: pharmacological and endocrinological implications.氨鲁米特的酶诱导作用：药理学及内分泌学意义
Cancer Chemother Pharmacol. 1990;26(4):241-4. doi: 10.1007/BF02897223.
本文引用的文献
1
Studies of oestrogen metabolism in postmenopausal women with cancer.绝经后癌症女性雌激素代谢的研究。
J Steroid Biochem. 1981 Dec;15:235-45. doi: 10.1016/0022-4731(81)90280-6.
2
Preservation of androgen secretion during estrogen suppression with aminoglutethimide in the treatment of metastatic breast carcinoma.在使用氨鲁米特抑制雌激素治疗转移性乳腺癌期间雄激素分泌的保留情况。
J Clin Invest. 1980 Mar;65(3):602-12. doi: 10.1172/JCI109705.
3
Hydrocortisone alone vs hydrocortisone plus aminoglutethimide: a comparison of the endocrine effects in postmenopausal breast cancer.单独使用氢化可的松与氢化可的松加氨鲁米特的比较：绝经后乳腺癌内分泌效应的对比
Eur J Cancer Clin Oncol. 1984 Apr;20(4):463-9. doi: 10.1016/0277-5379(84)90230-x.
4
Endocrine changes associated with relapse in advanced breast cancer patients on aminoglutethimide therapy.接受氨鲁米特治疗的晚期乳腺癌患者复发相关的内分泌变化。
J Clin Endocrinol Metab. 1984 Jan;58(1):99-104. doi: 10.1210/jcem-58-1-99.
5
Aminoglutethimide dose and hormone suppression in advanced breast cancer.氨鲁米特剂量与晚期乳腺癌的激素抑制
Eur J Cancer Clin Oncol. 1983 Apr;19(4):493-8. doi: 10.1016/0277-5379(83)90112-8.
6
Endocrine effects of low dose aminoglutethimide alone in advanced postmenopausal breast cancer.低剂量氨鲁米特单药对晚期绝经后乳腺癌的内分泌作用
Br J Cancer. 1983 May;47(5):621-7. doi: 10.1038/bjc.1983.100.
7
Endocrine and therapeutic effects of aminoglutethimide in premenopausal patients with breast cancer.氨鲁米特对绝经前乳腺癌患者的内分泌及治疗作用
J Clin Endocrinol Metab. 1982 Oct;55(4):718-22. doi: 10.1210/jcem-55-4-718.
8
Low-dose aminoglutethimide in treatment of advanced breast cancer.低剂量氨鲁米特治疗晚期乳腺癌
Lancet. 1984 Sep 15;2(8403):604-7. doi: 10.1016/s0140-6736(84)90596-8.
9
Proceedings: Medical adrenalectomy using aminoglutethimide and dexamethasone in advanced breast cancer.会议记录：在晚期乳腺癌中使用氨鲁米特和地塞米松进行肾上腺切除术
Cancer. 1974 Feb;33(2):503-12. doi: 10.1002/1097-0142(197402)33:2<503::aid-cncr2820330227>3.0.co;2-l.
10
Source of estrogen production in postmenopausal women.绝经后女性雌激素的产生来源。
J Clin Endocrinol Metab. 1973 Feb;36(2):207-14. doi: 10.1210/jcem-36-2-207.
Zotero 插件